Abstract Library

#4514 Liver debulking surgery is benefit to PFS in patients with high tumour burden of neuroendocrine tumour liver metastases

Introduction: Liver debulking surgery has shown its definite effect on prolonging survival in patients with neuroendocrine tumour liver metastases (NETLM). However, the effect of liver debulking surgery on the high burden of NETLM is still not clear.

Conference:

Presenting Author:

Authors: Zhou J, Liang Y, Chen J, Wang L,

Keywords: liver debulking surgery, NETLM,

#4447 Efficacy and safety analysis of XELOX plus bevacizumab in the treatment of metastatic NETs

Introduction: For patients with advanced NETs, standardised treatment protocols based on guideline consensus form the foundation, yet individualised interpretation and flexible application of these guidelines are essential.

Conference:

Presenting Author: Wang H

Authors: Wang H, Zhou Y, Tan H, Sun Y, Chi Y,

Keywords: advanced neuroendocrine tumour, combination therapy, drug therapy, retrospective study, combined chemotherapy targeting,

#4410 NETest can predict the tumour burden in neuroendocrine tumours

Introduction: Neuroendocrine tumours (NETs) are rare malignancies characterised by slow growth and a lack of reliable biomarkers for predicting tumour burden, treatment response, and prognosis.

Conference:

Presenting Author:

Authors: You T, Zhou N, Tang H, Ying J, Wang C,

Keywords: NETest, biomarker, NET,

#4374 Efficacy and safety of immunotherapy combined with antiangiogenesis agents and temozolomide in neuroendocrine carcinoma

Introduction: Platinum-based doublet chemotherapy is the standard first-line treatment, without standard treatment for second-line or subsequent systemic therapy for recurrent or progressive advanced neuroendocrine cancer (NEC).

Conference:

Presenting Author:

Authors: Li X, Yang M, Fan Q, Song L,

Keywords: Neuroendocrine carcinoma, Immunotherapy, Antiangiogenesis agents, Temozolomide,

#4166 Characterising the tumor microenvironment of multifocal small intestinal NETs

Introduction: Small intestinal neuroendocrine tumors (SI-NETs) are thought to arise from enterochromaffin cells of the gut, often with multiple synchronous primary tumors. Recently, we showed that synchronous primary tumors from the same SI-NET patient display distinct somatic mutational profiles, suggesting that these tumors originate independently, despite few clear driver mutations. Thus, new mechanistic insights into multifocal SI-NETs are urgently needed.

Conference:

Presenting Author:

Authors: Mäkinen N, Lee I, Dohlman A, Gao T, Zhang Z,

Keywords: small intestinal NET, tumor microenvironment, tumor microbiome,